Marks Group Wealth Management Inc Sells 1,839 Shares of IDEXX Laboratories, Inc. $IDXX

Marks Group Wealth Management Inc lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,101 shares of the company’s stock after selling 1,839 shares during the period. Marks Group Wealth Management Inc’s holdings in IDEXX Laboratories were worth $6,453,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. WealthCollab LLC purchased a new stake in IDEXX Laboratories during the second quarter valued at about $30,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $31,000. Armstrong Advisory Group Inc. lifted its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares in the last quarter. Salomon & Ludwin LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth approximately $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $35,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on IDXX. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Morgan Stanley boosted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 7th. Finally, UBS Group decreased their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $635.66 on Monday. The stock has a market cap of $50.76 billion, a price-to-earnings ratio of 48.64, a PEG ratio of 3.87 and a beta of 1.67. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The business has a 50-day simple moving average of $677.74 and a 200 day simple moving average of $669.32. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the business posted $2.53 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 18,180 shares of company stock valued at $11,626,996 in the last quarter. Corporate insiders own 0.98% of the company’s stock.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.